These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37220263)

  • 1. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.
    Rodriguez-Valadez JM; Tahsin M; Fleischmann KE; Masharani U; Yeboah J; Park M; Li L; Weber E; Li Y; Berkalieva A; Max W; Hunink MGM; Ferket BS
    Diabetes Care; 2023 Jun; 46(6):1300-1310. PubMed ID: 37220263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
    Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
    Rodriguez-Valadez JM; Tahsin M; Masharani U; Park M; Hunink MGM; Yeboah J; Li L; Weber E; Berkalieva A; Avezaat L; Max W; Fleischmann KE; Ferket BS
    J Am Heart Assoc; 2024 Feb; 13(4):e032463. PubMed ID: 38362889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
    Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M; Dietrich JW; Nauck MA; Lim S
    Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Cardiol Res; 2023 Feb; 14(1):12-21. PubMed ID: 36896226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus.
    Albert SG; Shrestha E; Ahir V
    Endocr Pract; 2024 Mar; 30(3):246-252. PubMed ID: 38097111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
    Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.
    Palanca A; Ampudia-Blasco FJ; Calderón JM; Sauri I; Martinez-Hervás S; Trillo JL; Redón J; Real JT
    Diabetes Res Clin Pract; 2024 Jan; 207():111071. PubMed ID: 38142748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.